Advertisement

CQ38. Does Combined Modality Therapy for Anaplastic Carcinoma Improve Prognosis?

  • Kiminori Sugino
  • Naoyoshi Onoda
Chapter

Abstract

Most anaplastic carcinomas are locally progressive and show distant metastasis at diagnosis. To control local and distant lesions and improve the survival rates and QOL, combined modality therapy is performed. In the past, responders obtained prolonged survival rates, although there are no reports for effective regimens. However, therapy evaluation should be performed frequently and a change of therapeutic strategy is necessary when the current treatment is judged ineffective.

Keywords

Distant Metastasis External Beam Radiotherapy Effective Regimen Weekly Paclitaxel Anaplastic Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Pudney D, Lau H, Faick V (2007) Clinical experience of the multimodality management of anaplastic thyroid cancer and literature review. Thyroid 17:1243–1250 (RS)PubMedCrossRefGoogle Scholar
  2. 2.
    Wang Y, Tsang R, Asa S et al (2006) Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer 107:1786–1792 (RS)PubMedCrossRefGoogle Scholar
  3. 3.
    De Crevoisier R, Baudin E, Bachelot A et al (2004) Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 60:1137–1143 (PS)PubMedCrossRefGoogle Scholar
  4. 4.
    Tennvall J, Lundell G, Wahlberg P et al (2002) Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 86:1848–1853 (PS)PubMedCrossRefGoogle Scholar
  5. 5.
    Besic N, Auersperg M, Us-Krasovec M et al (2001) Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg Oncol 27:260–264 (RS)PubMedCrossRefGoogle Scholar
  6. 6.
    Ain KB, Egorin MJ, DeSimone PA (2000) Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Thyroid 10:587–594 (PS)PubMedCrossRefGoogle Scholar
  7. 7.
    Busnardo B, Daniele O, Pelizzo MR et al (2000) A multimodality thrapeutic approach in anaplastic thyroid carcinoma; study on 39 patients. J Endocrinol Invest 23:755–761 (RS)PubMedGoogle Scholar
  8. 8.
    Passler C, Scheuba C, Prager G et al (1999) Anaplastic (undifferentiated) thyroid carcinoma (ATC). A retrospective analysis. Langenbeck’s Arch Surg 384:284–293 (RS)CrossRefGoogle Scholar
  9. 9.
    Kobayashi T, Asakawa H, Umeshita K et al (1996) Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck 18:36–41 (RS)PubMedCrossRefGoogle Scholar
  10. 10.
    Chemotherapy Committee, The Japanese Society of Thyroid Surgery (1995) Intensive chemotherapy for anaplastic thyroid carcinoma: combination of cisplatin, doxorubicin, etoposide and peplomycin with granulocyte colony-stimulating factor support. Jpn J Clin Oncol 25:203–207 (RS)Google Scholar
  11. 11.
    Tennvall J, Lundell G, Hallquist A et al (1994) Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group. Cancer 74:1348–1354 (RS)PubMedCrossRefGoogle Scholar
  12. 12.
    Levendag PC, De Porre PM, van Putten WL (1993) Anaplastic carcinoma of the thyroid gland treated by radiation therapy. Int J Radiat Oncol Biol Phys 26:125–128 (RS)PubMedCrossRefGoogle Scholar
  13. 13.
    Schlumberger M, Parmentier C, Delisle MJ et al (1991) Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer 67:564–566 (PS)PubMedCrossRefGoogle Scholar
  14. 14.
    Chang HS, Nam KH, Chung WY et al (2005) Anaplastic thyroid carcinoma: a therapeutic dilemma. Yonsei Med J 46:759–764 (RS)PubMedCrossRefGoogle Scholar
  15. 15.
    Yamashita T, Shimaoka K, Ito K et al (1992) (Text in Japanese) Naibunpitsugeka 9:213–218 (RS)Google Scholar
  16. 16.
    Sugino K, Ito K, Mimura T et al (2002) The important role of operations in the management of anaplastic thyroid carcinoma. Surgery 131:245–248 (RS)PubMedCrossRefGoogle Scholar
  17. 17.
    Higashiyama T, Ito Y, Hirokawa M et al (2010) Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 20:7–14 (RS)PubMedCrossRefGoogle Scholar
  18. 18.
    Sugitani I, Kasai N, Fujimoto Y et al (2001) Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg 25:617–622 (RS)PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2013

Authors and Affiliations

  1. 1.Department of SurgeryIto HospitalTokyoJapan
  2. 2.Department of Surgical OncologyOsaka City University Graduate School of MedicineOsakaJapan

Personalised recommendations